Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLQ | O75417 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RHEB | Q15382 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587739 | 0.84 | NOTUM (0.45) | HSD11B1NOTUMHTTLMNAS1PR1 | |
| SCHEMBL3894448 | 0.82 | HTT (0.41) | CYP3A4RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8737846 | 0.79 | AR (0.60) | CYP1A2CYP2C19KDM4ERHEB | |
| SCHEMBL10167452 | 0.79 | MAPT (0.45) | SMN1; SMN2TP53MAPTS1PR1 | |
| SCHEMBL5744183 | 0.79 | CYP3A4 (0.48) | CYP3A4CYP1A2CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL3789153 | 0.78 | CYP3A4 (0.52) | CYP3A4RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5949403 | 0.76 | NOTUM (0.53) | NOTUMS1PR1 | |
| SCHEMBL987352 | 0.76 | IDO1 (0.50) | CYP3A4RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL84053 | 0.76 | SMN1; SMN2 (0.44) | CYP1A2SMN1; SMN2TP53NOTUMRAPGEF4 | |
| SCHEMBL30742956 | 0.76 | NOTUM (0.53) | NOTUMS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112676307-A | Method for reducing and recycling catalyst residues | 江苏优普生物化学科技股份有限公司 | 2021-04-20 | — | — | CN | claimed |
| US-5600036-A | 2-trifluoromethyl-4-chlorobenzalchloride and 2-methyl-3-nitro-5-chlorobenzotrifluoride useful as intermediates for preparing 2-methyl-3-aminobenzotrifluoride | CENTRAL GLASS COMPANY, LIMITED (JP) | 1997-02-04 | — | — | US | claimed |
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11319319-B1 | Compounds for inhibiting NLRP3 and uses thereof | VENTUS THERAPEUTICS U.S., INC. (US) | 2022-05-03 | — | — | US | disclosed |
| CN-114181074-A | Preparation method of p-chlorobenzoyl fluoride | 大连奇凯医药科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-11225469-B2 | Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-01-18 | — | — | US | disclosed |
| CN-113710788-A | Solvent composition and use thereof | 株式会社金子化学 | 2021-11-26 | — | — | CN | disclosed |
| CN-113661203-A | Acrylic modified polymeric sunscreen agents for use in organic media | 阿科玛股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| WO-2021226629-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3892618-A1 | 4-PYRIDINYL FORMAMIDE COMPOUND OR DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | Qingdao KingAgroot Chemical Compound Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| US-7220765-B2 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) | 2007-05-22 | — | — | US | disclosed |
| US-20070093529-A1 | Diacylhydrazine derivatives | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093529-A1 | Diacylhydrazine derivatives | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | disclosed |
| US-5600036-A | 2-trifluoromethyl-4-chlorobenzalchloride and 2-methyl-3-nitro-5-chlorobenzotrifluoride useful as intermediates for preparing 2-methyl-3-aminobenzotrifluoride | CENTRAL GLASS COMPANY, LIMITED (JP) | 1997-02-04 | — | — | US | disclosed |
| US-5600036-A | 2-trifluoromethyl-4-chlorobenzalchloride and 2-methyl-3-nitro-5-chlorobenzotrifluoride useful as intermediates for preparing 2-methyl-3-aminobenzotrifluoride | CENTRAL GLASS COMPANY, LIMITED (JP) | 1997-02-04 | — | — | US | disclosed |
| US-5449831-A | Process of preparing 2-methyl-3-aminobenzotrifluoride | CENTRAL GLASS COMPANY, LIMITED (JP) | 1995-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | CYP3A4 2798/4885RAB9A 2774/4885CYP1A2 1383/4885 |
| US-11225469-B2 | Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof | PHGDH, PGD, PGK1 | CYP3A4 1161/4885RAB9A 1994/4885CYP1A2 1301/4885 |
| US-20070093529-A1 | Diacylhydrazine derivatives | BRAF, RAF1, NRAS | CYP3A4 1795/4885RAB9A 2043/4885CYP1A2 559/4885 |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | GHSR, IGF1R, GIPR | CYP3A4 4264/4885RAB9A 2756/4885CYP1A2 4075/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | CYP3A4 2041/4885RAB9A 3815/4885CYP1A2 685/4885 |
| US-11319319-B1 | Compounds for inhibiting NLRP3 and uses thereof | NLRP3, NLRP1, PYCARD | CYP3A4 4080/4885RAB9A 2945/4885CYP1A2 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.